U.S. stocks edge higher after weekly jobless claims; Salesforce gains
Investing.com - UBS maintained its Neutral rating and $90.00 price target on Edwards Lifesciences (NYSE:EW) ahead of the company’s Investor Day scheduled for December 4. The stock currently trades at $84.61, closely aligned with InvestingPro’s Fair Value assessment, suggesting the shares are fairly priced.
The decision comes as analyst sentiment has shifted more positively following better-than-feared long-term TAVR (Total Aortic Valve Replacement) data released in late October. This positive shift aligns with the stock’s strong performance, having delivered a 20.67% return over the past year.
UBS expects Edwards Lifesciences to provide 2026 guidance that aligns with current investor expectations, with little controversy anticipated for what is typically considered a battleground stock.
The firm projects Edwards will guide for global TAVR sales growth in the high-single-digit range of 6-8%, consistent with both UBS and consensus estimates of approximately 7% on a dollar basis.
Management has seemingly reiterated its previously issued long-term guidance as recently as the third quarter 2025 earnings call, suggesting continuity in the company’s outlook.
In other recent news, Edwards Lifesciences reported impressive financial results for the third quarter of 2025, with an adjusted earnings per share of $0.67, surpassing Wall Street’s forecast of $0.59. The company’s revenue also exceeded expectations, reaching $1.55 billion compared to the projected $1.5 billion. Bernstein has acknowledged the company’s strong quarterly performance by raising its price target to $90.00, citing growth in the transcatheter aortic valve replacement (TAVR) business. Canaccord Genuity also increased its price target to $84.00, maintaining a Hold rating after Edwards Lifesciences delivered 12.6% year-over-year adjusted growth. Raymond James upgraded the company’s stock rating to Outperform, with a new price target of $96.00, reflecting a more optimistic view of the company’s prospects. Piper Sandler reiterated an Overweight rating with a price target of $95.00, ahead of the company’s annual investor day. These developments underscore the positive momentum Edwards Lifesciences is experiencing across its business segments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.